Merck rains on Roche's parade with double Keytruda win in squamous lung cancer
admin 23rd May 2018 Uncategorised 0Merck already controls a big piece of the first-line non-small cell lung cancer market, and it likely just secured most of the rest. Its immunotherapy Keytruda nailed a study in previously untreated patients with the squamous form of the disease, who represent up to 30% of newly diagnosed NSCLC cases.
More: Merck rains on Roche's parade with double Keytruda win in squamous lung cancer
Source: fierce